CFTR and cystic fibrosis: Trikafta, a triple-combination drug composed of two CFTR correctors (tezacaftor/VX-661, elexacaftor/VX-445) and one CFTR potentiator (ivacaftor/VX-770), has been therapeutically used for CF with ∆F508-CFTR as it restores PM expression and function of CFTR with structural abnormalities [52,53].